Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)

Tri Nguyen; Rebecca Parker; Elisa Hawkins; Beata Holkova; Victor Yazbeck; Akhil Kolluri; Maciej Kmieciak; Mohamed Rahmani; Steven Grant

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)

Tri Nguyen
, Rebecca Parker
, Elisa Hawkins
, Beata Holkova
, Victor Yazbeck
, Akhil Kolluri
, Maciej Kmieciak
, Mohamed Rahmani
, Steven Grant

College of Medicine and Health Sciences

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

This article has been corrected: Due to errors in image assembly, the IVIS image for the control mouse (panel 3) was inadvertently duplicated as the volasertib-treated mouse (panel 2) at time 0 (d1) in Figure 6A. After reviewing the original files, the correct image for the volasertib-treated time 0 (d1) mouse (panel 2) was located. The corrected Figure 6A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented).

Original language	British English
Pages (from-to)	5383-5384
Number of pages	2
Journal	Oncotarget
Volume	10
Issue number	51
State	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Fingerprint

Dive into the research topics of 'Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)'. Together they form a unique fingerprint.

Cite this

Nguyen, T., Parker, R., Hawkins, E., Holkova, B., Yazbeck, V., Kolluri, A., Kmieciak, M., Rahmani, M., & Grant, S. (2019). Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649). Oncotarget, 10(51), 5383-5384.

@article{085db7e305ff42d1b2f9c90136fa0d31,

title = "Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)",

abstract = "This article has been corrected: Due to errors in image assembly, the IVIS image for the control mouse (panel 3) was inadvertently duplicated as the volasertib-treated mouse (panel 2) at time 0 (d1) in Figure 6A. After reviewing the original files, the correct image for the volasertib-treated time 0 (d1) mouse (panel 2) was located. The corrected Figure 6A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented).",

author = "Tri Nguyen and Rebecca Parker and Elisa Hawkins and Beata Holkova and Victor Yazbeck and Akhil Kolluri and Maciej Kmieciak and Mohamed Rahmani and Steven Grant",

note = "Publisher Copyright: {\textcopyright} 2019 Nguyen et al.",

year = "2019",

language = "British English",

volume = "10",

pages = "5383--5384",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "51",

}

Nguyen, T, Parker, R, Hawkins, E, Holkova, B, Yazbeck, V, Kolluri, A, Kmieciak, M, Rahmani, M & Grant, S 2019, 'Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)', Oncotarget, vol. 10, no. 51, pp. 5383-5384.

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649). / Nguyen, Tri; Parker, Rebecca; Hawkins, Elisa et al.
In: Oncotarget, Vol. 10, No. 51, 2019, p. 5383-5384.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)

AU - Nguyen, Tri

AU - Parker, Rebecca

AU - Hawkins, Elisa

AU - Holkova, Beata

AU - Yazbeck, Victor

AU - Kolluri, Akhil

AU - Kmieciak, Maciej

AU - Rahmani, Mohamed

AU - Grant, Steven

PY - 2019

Y1 - 2019

N2 - This article has been corrected: Due to errors in image assembly, the IVIS image for the control mouse (panel 3) was inadvertently duplicated as the volasertib-treated mouse (panel 2) at time 0 (d1) in Figure 6A. After reviewing the original files, the correct image for the volasertib-treated time 0 (d1) mouse (panel 2) was located. The corrected Figure 6A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented).

AB - This article has been corrected: Due to errors in image assembly, the IVIS image for the control mouse (panel 3) was inadvertently duplicated as the volasertib-treated mouse (panel 2) at time 0 (d1) in Figure 6A. After reviewing the original files, the correct image for the volasertib-treated time 0 (d1) mouse (panel 2) was located. The corrected Figure 6A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented).

UR - https://www.scopus.com/pages/publications/85072038703

M3 - Comment/debate

C2 - 31523396

AN - SCOPUS:85072038703

SN - 1949-2553

VL - 10

SP - 5383

EP - 5384

JO - Oncotarget

JF - Oncotarget

IS - 51

ER -

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this